Everest Biotech Offers International $100,000 Antibody Grant
News May 04, 2010
Everest Biotech, a manufacturer of high quality novel antibodies for the international research market, announces the launch of its Antibody Creation Grant. Worth up to $100,000, the funding is on offer to research labs around the world before the deadline of 31st July 2010.
Everest Biotech has manufactured more than 2000 affinity purified polyclonal antibodies against novel targets for its own catalogue. Soon, its production line could be working for your lab - if you could use between 20 and 100 novel antibodies to advance your research, the company says.
To apply for the grant, applicants need to follow two simple steps:
1. Select 5–50 target proteins for which there is a need for new antibodies and that your lab can characterize.
2. Fill in a short application form available at http://everestbiotech.com and send it to email@example.com.
Everest Biotech’s scientific panel will judge entries. Once the grant is awarded, Everest Biotech’s team will work with you to pick two peptide antigens for each target protein, synthesize it and then immunize goats. You will receive 2 mg of affinity-purified goat polyclonal antibody against each peptide at no cost. Everest Biotech will commercialize the remainder of the batch. Affinity-purified anti-peptide polyclonal antibodies come closest to monoclonal antibodies, yet have higher affinity and are better suited for a wide range of applications. Goats produce larger batches than rabbits and, therefore, their antibodies are preferred over other polyclonal antibodies for bulk applications where monoclonal antibodies fail.
“We’re very excited to offer this grant to the international biomedical research community. The aim of our Antibody Creation Grant is to provide financial support to researchers needing novel antibodies and demonstrates Everest Biotech’s commitment to research. A new set of good reagents, widely available, has the potential to transform a research field – I have seen it many times,” commented Professor Neil Barclay from the Sir William Dunn School of Pathology at the University of Oxford and Chairman of Everest Biotech.
6th World Congress on Human Genetics and Genetic Diseases
Apr 08 - Apr 09, 2019